Related Experiment Video
Updated: Dec 25, 2025

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
Published on: April 18, 2019
Innovation in Antimicrobial Resistance: The CARB-X Perspective
Richard A Alm1, Karen Gallant1
1CARB-X, Boston University, Boston, Massachusetts 02215, United States.
Abstract:
The spread of drug-resistant bacterial pathogens has been recognized as one of the largest global threats to mankind. In order to continue to benefit from the advancement of modern medicine, new treatments, prevention, and diagnostic products are needed to satisfactorily treat or prevent infections. Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is a global nonprofit public-private partnership dedicated to accelerating antibacterial-related research to tackle the rising threat of drug-resistant bacteria. The CARB-X portfolio is the world's largest early development pipeline of new antibiotics, vaccines, rapid diagnostics, and other products to prevent, diagnose, and treat life-threatening bacterial infections. Since inception, three application rounds of funding have been completed with a significant worldwide response.
More Related Videos
Related Concept Videos
Development of Antibiotic Resistance
Antibiotic Selection
Gene Regulation in Microbial Communities: Quorum Sensing
Antimicrobial Effectiveness

